logo
  

Crown Castle International Q1 Results Top Estimates

Crown Castle International Corp. (CCI) reported net income for the first quarter of $112 million or $0.34 per share, compared to $91 million or $0.27 per share for the yar-ago quarter.

Funds from Operations for the first quarter increased 11% to $373 million or $1.12 per share in the first quarter, compared to $338 million or $1.01 per share in the prior year quarter.

Adjusted Funds from Operations increased 10% to $383 million or $1.15 per share in the first quarter of 2015, compared to $349 million or $1.05 per share in the first quarter of last year.

Total revenues for the first quarter rose 7% to $941 million from $876 million a year earlier.

Analysts polled by Thomson Reuters expected the company to report FFO of $1.09 per share on revenue of $936.52 million for the first quarter. Analysts' estimates typically exclude special items.

Looking forward to the second quarter, the company forecasts adjusted FFO of $1.04 to $1.06 per share.

For the full year 2015, the company now forecasts adjusted FFO of $4.34 to $4.39 per share, compared to its prior guidance of $4.33 to $4.39 per share.

Analysts currently expect the company to report FFO of $1.09 per share for the second quarter and $4.40 per share for the full year 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT